EBITDA at other companies
Other financials
Where this comes from
Calculated from Design Therapeutics, Inc.’s reported figures.
The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Design Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Design Therapeutics, Inc.'s EBITDA?
- Design Therapeutics, Inc. (DSGN) reported EBITDA of -$19.55M in Q1 2026.
- How has Design Therapeutics, Inc.'s EBITDA changed year-over-year?
- Design Therapeutics, Inc.'s EBITDA increased by 3.5% year-over-year, from -$20.26M to -$19.55M.
- What is the long-term trend for Design Therapeutics, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s EBITDA has grown at a 21.9% compound annual growth rate (CAGR), from -$35.7M to -$78.85M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.